ReviewInternational journal of molecular sciences2022
Renal Oncocytoma: The Diagnostic Challenge to Unmask the Double of Renal Cancer.
Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.
- CT radiomics for differentiating oncocytoma from renal cell carcinomas: Systematic review and meta-analysis.Clinical imaging · 2023Pooled it
- A cfDNA fragmentomics classifier for noninvasive differentiation of benign and malignant renal masses.Molecular biomedicine · 2026Article
- Prospective evaluation ofAnnals of nuclear medicine · 2026Article
- Artificial Intelligence in Renal Imaging: A Multi-Dataset Study for Kidney Disease Classification.Biomedicines · 2026Article
- Not all masses are metastases: a diagnostic dilemma resolved - synchronous HER2-positive breast cancer and renal oncocytoma.International journal of surgery case reports · 2026Article
- Clinical Management of Synchronous and Metachronous Renal Lesions in Patients With Oncocytoma Treated With Nephrectomy: A 30-Year Single-Center Experience.Clinical genitourinary cancer · 2026Article
- Emerging Role of ctDNA Fragmentomics and Epigenetic Signatures in the Early Detection, Minimal Residual Disease Assessment, and Precision Monitoring of Renal Cell Carcinoma.Journal of cellular and molecular medicine · 2026Review
- Multiphase CT-derived markers for the characterization of large solid and cystic renal masses by histology and grade.Polish journal of radiology · 2026Article
- Development of a clinical nomogram for predicting hemorrhagic rupture in renal angiomyolipoma and analysis of molecular correlates (Open medicine (Warsaw, Poland) · 2026Article
- Article
- Intratumoral and peritumoral radiomics using multi-phase contrast-enhanced CT for diagnosis of renal oncocytoma and chromophobe renal cell carcinoma: a multicenter retrospective study.Frontiers in oncology · 2025Article
- Renal Oncocytoma Treated With Stereotactic Body Radiation Therapy in a Patient With Prior Pancoast Tumor.Cureus · 2025Article
- Multifocal, multiphenotypic tumours arising from an MTOR mutation acquired in early embryogenesis.Oncogene · 2024Article
- Multiparameter computed tomography (CT) radiomics signature fusion-based model for the preoperative prediction of clear cell renal cell carcinoma nuclear grade: a multicenter development and external validation study.Quantitative imaging in medicine and surgery · 2024Article
- Significance and Possible Biological Mechanism forWorld journal of oncology · 2024Article
- Multiparametric MRI for characterization of the tumour microenvironment.Nature reviews. Clinical oncology · 2024Review
- Renomedullary Interstitial Cell Tumor in the Background of a Renal Oncocytoma: A Case Report.Cureus · 2024Article
- The Use of Radiomic Tools in Renal Mass Characterization.Diagnostics (Basel, Switzerland) · 2023Review
- Radiomics vs radiologist in bladder and renal cancer. Results from a systematic review.Central European journal of urology · 2023Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal oncocytoma represents the most common type of benign neoplasm that is an increasing concern for urologists, oncologists, and nephrologists due to its difficult differential diagnosis and frequent overtreatment. It displays a variable neoplastic parenchymal and stromal architecture, and the defining cellular element is a large polygonal, granular, eosinophilic, mitochondria-rich cell known as an oncocyte. The real challenge in the oncocytoma treatment algorithm is related to the misdiagnosis due to its resemblance, at an initial radiological assessment, to malignant renal cancers with a completely different prognosis and medical treatment. Unfortunately, percutaneous renal biopsy is not frequently performed due to the possible side effects related to the procedure. Therefore, the majority of oncocytoma are diagnosed after the surgical operation via partial or radical nephrectomy. For this reason, new reliable strategies to solve this issue are needed. In our review, we will discuss the clinical implications of renal oncocytoma in daily clinical practice with a particular focus on the medical diagnosis and treatment and on the potential of novel promising molecular biomarkers such as circulating microRNAs to distinguish between a benign and a malignant lesion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.